{"id":"a3b76dbba676","type":"article","url":"https://hartvaat.nl/2026/02/25/behandeling-van-familiaire-hypercholesterolemie-bij-kinderen-3-jaar-lipigen-regi/","title":"Behandeling van familiaire hypercholesterolemie bij kinderen: 3 jaar LIPIGEN-register","title_en":"Real-world management of familial hypercholesterolemia in paediatric patients: a 3-year follow-up from the LIPIGEN registry","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","huisarts","internist"],"tags":["dyslipidemie","ezetimibe","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","ldl-cholesterol","lipidenverlaging","statines","vrouwen"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(26)00057-2/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(26)00057-2/fulltext","authors":["Federica Galimberti","Maria Elena Capra","Elena Olmastroni","Davide Braghiroli","Giuseppe Banderali","Francesco Baratta","Giacomo Biasucci","Marta Biolo","Paola Sabrina Buonuomo","Angelo Baldassare Cefalù","Francesco Cipollone","Nadia Citroni","Sergio D'Addato","Simonetta Genovesi","Ornella Guardamagna","Lorenzo Iughetti","Giuseppe Mandraffino","Ilenia Minicocci","Giuliana Germana Mombelli","Tiziana Montalcini","Fabio Nascimbeni","Angelina Passaro","Matteo Pirro","Elisabetta Rinaldi","Francesco Sbrana","Roberto Scicali","Patrizia Suppressa","Pablo Josè Werba","Maria Grazia Zenti","Marcello Arca","Maurizio Averna","Patrizia Tarugi","Sebastiano Calandra","Alberico Luigi Catapano","Cristina Pederiva","Manuela Casula","the LIPIGEN Paediatric Group"],"significance":5,"published":"2026-02-25","source_date":"2026-02-25","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/familiaire-hypercholesterolemie/","https://hartvaat.nl/kennis/preventie/levenslang-cardiovasculair-risico/"],"congress":"","summary_en":"Data from the Italian LIPIGEN registry describe the timing, pharmacological approach, and early outcomes of lipid-lowering therapy initiation in children with familial hypercholesterolaemia. Early identification and treatment are crucial for reducing lifetime cardiovascular risk.","created":"2026-07-03T10:24:54Z","updated":"2026-07-03T13:24:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Data uit het Italiaanse LIPIGEN-register beschrijven het moment van starten, de farmacologische aanpak en de vroege uitkomsten van lipidenverlagende therapie bij kinderen en adolescenten met familiaire hypercholesterolemie. Vroege identificatie en behandeling zijn cruciaal om het levenslange cardiovasculaire risico te verlagen.","abstract_original":"Familial hypercholesterolemia (FH) is a common genetic disorder characterized by elevated low-density lipoprotein cholesterol (LDL-C) from early life, significantly increasing lifetime risk of atherosclerotic cardiovascular disease. Early identification and initiation of lipid-lowering therapy (LLT) are crucial. This study aimed to describe the timing, pharmacological approach, and early outcomes of LLT initiation in children and adolescents with FH from the Italian LIPIGEN registry."}